Trial Profile
An open label, randomised, two period, two treatment, cross over study to compare pharmacokinetics and anticoagulant effects of Rivaroxaban and Apixaban at doses approved for stroke prevention in nonvalvular atrial fibrillation patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2017
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Apixaban
- Indications Stroke
- Focus Pharmacodynamics; Pharmacokinetics
- 22 Aug 2017 New trial record
- 14 Aug 2017 Results published in the Journal of Thrombosis and Haemostasis